明德生物(002932.SZ)半年度淨利潤預增162.78%-212.73%
格隆匯7月13日丨明德生物(002932.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤5.26億元-6.26億元,同比增長162.78%-212.73%;歸屬於上市股東的扣除非經常性損益的淨利潤5.2億元-6.2億元,同比增長158.91%-208.71%。主要原因如下:
1、疫情爆發以來公司新增了1500多家分子診斷等級醫療機構客户,基於國家疫情防控的要求,公司持續為上述客户提供新冠核酸檢測試劑和其它分子診斷產品,帶來公司新冠核酸檢測試劑及分子診斷相關儀器銷售大幅增長;
2、報吿期內,公司產品線日益完善,化學發光免疫分析儀CF10及相關檢測試劑、血氣診斷儀器PT1000及相關檢測試劑銷售均同比大幅增長;
3、公司深耕三年的急危重症信息化解決方案持續迭代升級,在基層醫療和等級醫院中滲透率逐步提高,相關收入穩步增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.